Compounds > matrine, (5beta)-isomer
Page last updated: 2024-11-08

matrine, (5beta)-isomer

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID165549
CHEMBL ID1824581
SCHEMBL ID564578
MeSH IDM0320043

Synonyms (43)

Synonym
matridin-15-one, (5-beta)-
5-epidihydrosophocarpine
sophoridin
(5-beta)-matridin-15-one
dihydro-5-episophocarpine
sophoridine
AC-11149
STK801895
(5beta)-matridin-15-one
AKOS004119815
CHEMBL1824581
BBL010922
6882-68-4
w5s1m800j7 ,
unii-w5s1m800j7
S3895
SCHEMBL564578
DTXSID60218927
smr000445708
MLS006011816
Q-100773
sophoridine [who-dd]
1h,5h,10h-dipyrido(2,1-f:3',2',1'-ij)(1,6)naphthyridin-10-one, dodecahydro-, (7ar-(7a.alpha.,13a.alpha.,13b.beta.,13c.beta.))-
(-)-sophoridine
6-allomatrine
6.beta.-matrine
ZSBXGIUJOOQZMP-BHPKHCPMSA-N
tetrahydroisosophoramine
matridin-15-one, (6.beta.)-
J-524280
mfcd00238686
M3093
DS-3313
(41s,7ar,13ar,13br)-dodecahydro-1h,5h,10h-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10-one
6882-68-4 (free)
(41s,7ar,13ar,13br)-dodecahydro-1h-dipyrido[2,1-f:3',2',1'-ij][1,6]naphthyridin-10(41h)-one
sophoridine,(s)
HMS3885C12
CCG-266944
Q27292355
HY-N1373
CS-0016780
(1r,2r,9r,17s)-7,13-diazatetracyclo[7.7.1.02,7.013,17]heptadecan-6-one

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" It also showed a moderate oral bioavailability and good safety in vivo."( Novel N-substituted sophoridinol derivatives as anticancer agents.
Bi, CW; Deng, HB; Li, YH; Shao, RG; Song, DQ; Tang, S; Wang, Z; Zhang, CX; Zhao, WL, 2014)		0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (33)

Assay IDTitleYearJournalArticle
AID1171349Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Synthesis and biological evaluation of sophoridinol derivatives as a novel family of potential anticancer agents.
AID1397252Antiproliferative activity against human HeLa cells by MTT assay2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Design, synthesis and evaluation of novel sophoridinic imine derivatives containing conjugated planar structure as potent anticancer agents.
AID617145Inhibition of DNA topoisomerase 1 using DNA substrate after 0.5 hrs by gel electrophoresis2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
Synthesis, structure-activity relationship and biological evaluation of anticancer activity for novel N-substituted sophoridinic acid derivatives.
AID1361509Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents.
AID1242263Immunoregulatory activity in BALC/c mouse assessed as reduction in DC cells at 60 mg/kg, ip once daily for 8 days by flow cytometry2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID1278838Antiproliferative activity against human MCF7 cells after 3 days by SRB assay2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Alkaloids from Oxytropis ochrocephala and antiproliferative activity of sophoridine derivatives against cancer cell lines.
AID1407981Antiproliferative activity against human HepG2 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis, biological evaluation and structure-activity relationship of sophoridine derivatives bearing pyrrole or indole scaffold as potential antitumor agents.
AID1361516Antitumor activity against human HepG2 cells xenografted in BALB/C nude mouse assessed as tumor weight at 40 mg/kg, ip treated twice per week for 25 days (Rvb = 0.84 +/- 0.09 g)2018European journal of medicinal chemistry, Aug-05, Volume: 156Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents.
AID1242264Immunoregulatory activity in BALC/c mouse assessed as reduction in NK cells at 60 mg/kg, ip once daily for 8 days by flow cytometry2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID1361507Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 48 hrs by MTT assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents.
AID1387671Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion at 0.4 mM supplemented with fresh medium containing compound every 3 days for 9 days measured after 9 days by ELISA relative to control2018Journal of natural products, 10-26, Volume: 81, Issue:10
Matrine-Type Alkaloids from the Roots of Sophora flavescens and Their Antiviral Activities against the Hepatitis B Virus.
AID1242261Immunoregulatory activity in BALC/c mouse assessed as increase in CD8+ T cells at 60 mg/kg, ip once daily for 8 days by flow cytometry2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID1361518Antitumor activity against human HepG2 cells xenografted in BALB/C nude mouse assessed as tumor growth at 40 mg/kg, ip treated twice per week for 25 days relative to control2018European journal of medicinal chemistry, Aug-05, Volume: 156Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents.
AID1143386Antiproliferative activity against human HepG2 cells assessed as growth inhibition after 48 hrs by MTT assay2014European journal of medicinal chemistry, Jun-23, Volume: 81Novel N-substituted sophoridinol derivatives as anticancer agents.
AID1242262Immunoregulatory activity in BALC/c mouse assessed as reduction in B cells at 60 mg/kg, ip once daily for 8 days by flow cytometry2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID1242269Antiviral activity against human enterovirus 71 infected in ICR mouse assessed as increase in survival rate at 15 mg/kg, ip qd for 8 days dosed 2 hrs post infection and measured at 14 days post infection relative to control2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID1361514Cell cycle arrest in human HepG2 cells accumulation at G1 phase at 2 to 6 mM after 24 hrs by propidium iodide staining-based flow cytometric analysis2018European journal of medicinal chemistry, Aug-05, Volume: 156Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents.
AID1171352Cell cycle arrest in human HepG2 cells assessed as accumulation at G0/G1 phase at 1.25 to 5 ug/ml after 24 hrs using propidium iodide by flow cytometry2014ACS medicinal chemistry letters, Nov-13, Volume: 5, Issue:11
Synthesis and biological evaluation of sophoridinol derivatives as a novel family of potential anticancer agents.
AID1242260Immunoregulatory activity in BALC/c mouse assessed as increase in CD4+ T cells at 60 mg/kg, ip once daily for 8 days by flow cytometry2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID1387675Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion at 0.4 mM supplemented with fresh medium containing compound every 3 days for 9 days measured after 9 days by ELISA relative to control2018Journal of natural products, 10-26, Volume: 81, Issue:10
Matrine-Type Alkaloids from the Roots of Sophora flavescens and Their Antiviral Activities against the Hepatitis B Virus.
AID1247222Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Oct-01, Volume: 25, Issue:19
Synthesis, structure-activity relationship and biological evaluation of novel nitrogen mustard sophoridinic acid derivatives as potential anticancer agents.
AID1242259Immunoregulatory activity in BALC/c mouse assessed as increase in CD3+ T cells at 60 mg/kg, ip once daily for 8 days by flow cytometry2015Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17
Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID1278836Antiproliferative activity against human KBVIN cells after 3 days by SRB assay2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Alkaloids from Oxytropis ochrocephala and antiproliferative activity of sophoridine derivatives against cancer cell lines.
AID1278835Antiproliferative activity against human KB cells after 3 days by SRB assay2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Alkaloids from Oxytropis ochrocephala and antiproliferative activity of sophoridine derivatives against cancer cell lines.
AID1361515Antitumor activity against human HepG2 cells xenografted in BALB/C nude mouse assessed as tumor volume at 40 mg/kg, ip treated twice per week for 25 days (Rvb = 1185.78 +/- 137.44 mm3)2018European journal of medicinal chemistry, Aug-05, Volume: 156Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents.
AID1397251Antiproliferative activity against human HepG2 cells by MTT assay2018Bioorganic & medicinal chemistry, 08-07, Volume: 26, Issue:14
Design, synthesis and evaluation of novel sophoridinic imine derivatives containing conjugated planar structure as potent anticancer agents.
AID1361508Cytotoxicity against human CNE2 cells assessed as reduction in cell viability after 48 hrs by MTT assay2018European journal of medicinal chemistry, Aug-05, Volume: 156Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents.
AID1278834Antiproliferative activity against human A549 cells after 3 days by SRB assay2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Alkaloids from Oxytropis ochrocephala and antiproliferative activity of sophoridine derivatives against cancer cell lines.
AID1760160Increase in glucose consumption in human HepG2 cells assessed as Gx/GDMSO ratio at 25 uM by glucose oxidase assay2020European journal of medicinal chemistry, Sep-01, Volume: 201Structure-activity relationship and hypoglycemic activity of tricyclic matrines with advantage of treating diabetic nephropathy.
AID1278837Antiproliferative activity against human MDA-MB-231 cells after 3 days by SRB assay2016Bioorganic & medicinal chemistry letters, Mar-01, Volume: 26, Issue:5
Alkaloids from Oxytropis ochrocephala and antiproliferative activity of sophoridine derivatives against cancer cell lines.
AID617131Inhibition of cell proliferation of human HepG2 cells at 30 ug/mL after 48 hrs by Sulforhodamine B assay2011Bioorganic & medicinal chemistry letters, Sep-15, Volume: 21, Issue:18
Synthesis, structure-activity relationship and biological evaluation of anticancer activity for novel N-substituted sophoridinic acid derivatives.
AID1408005Antitumor activity against human HepG2 cells xenografted in nude mouse assessed as tumor growth inhibition at 40 mg/kg for 25 days2018European journal of medicinal chemistry, Sep-05, Volume: 157Design, synthesis, biological evaluation and structure-activity relationship of sophoridine derivatives bearing pyrrole or indole scaffold as potential antitumor agents.
AID1387679Cytotoxicity against human HepG2.2.15 cells assessed as growth inhibition at 0.8 mM by MTT assay relative to control2018Journal of natural products, 10-26, Volume: 81, Issue:10
Matrine-Type Alkaloids from the Roots of Sophora flavescens and Their Antiviral Activities against the Hepatitis B Virus.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (90.91)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.02 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		2.2510guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		2.8730delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		2.5220taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
ribavirin
Rebetron: Rebetron is tradename		2.11101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
topotecan
Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.		2.110pyranoindolizinoquinolineantineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor
lamivudine
[no description available]		2.1710monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol		allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug
irinotecan
[no description available]		2.1710carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
rosiglitazone
[no description available]		2.2510aminopyridine;
thiazolidinediones		EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug
matrine
[no description available]		3.0740alkaloid
10-hydroxycamptothecin
[no description available]		2.0610pyranoindolizinoquinoline
oxymatrine
oxysophoridine: an alkaloid isolated from Sophra alope; structure in first source		2.5420alkaloid;
tertiary amine oxide
sophocarpine
[no description available]		2.8430
sophoramine
sophoramine: structure given in first source		2.8330naphthyridine derivative
doxorubicin hydrochloride
[no description available]		2.110anthracycline
melphalan
Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.		2.1110L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound		alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent
ConditionIndicatedRelationship StrengthStudiesTrials
Benign Neoplasms
[description not available]		02.0610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0610
Hand Foot and Mouth Disease
[description not available]		02.1110
Hand, Foot and Mouth Disease
A mild, highly infectious viral disease of children, characterized by vesicular lesions in the mouth and on the hands and feet. It is caused by coxsackieviruses A.		02.1110
Cancer of Liver
[description not available]		02.1710
Liver Neoplasms
Tumors or cancer of the LIVER.		02.1710
Experimental Hepatoma
[description not available]		02.1710
Alloxan Diabetes
[description not available]		02.2510
Diabetic Glomerulosclerosis
[description not available]		02.2510
Diabetic Nephropathies
KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.		02.2510